BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. - Wikidata - awgldk - TriplyDB

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

http://www.wikidata.org/entity/Q34539782

about

Role of Biomarkers in the Development of PARP Inhibitors Homozygous mutation of MTPAP causes cellular radiosensitivity and persistent DNA double-strand breaks.BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer The sesquiterpene lactone dehydroleucodine triggers senescence and apoptosis in association with accumulation of DNA damage markers.C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence.Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment The role of PARP1 in the DNA damage response and its application in tumor therapy.Reversion of the ErbB malignant phenotype and the DNA damage response.Resistance to PARP-Inhibitors in Cancer Therapy.DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.Tudor: a versatile family of histone methylation 'readers'.Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.Epistasis in genomic and survival data of cancer patients.A landscape of synthetic viable interactions in cancer.Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.Mechanisms of suppression: The wiring of genetic resilience.BRCA1 recruitment to damaged DNA sites is dependent on CDK9.Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses Mechanisms of oncogene-induced genomic instability.Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51.The Genome-Wide Interaction Network of Nutrient Stress Genes in Escherichia coli.Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors Aurora kinase B dependent phosphorylation of 53BP1 is required for resolving merotelic kinetochore-microtubule attachment errors during mitosis.Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytes Roles of BCCIP deficiency in mammary tumorigenesis.Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.PARP inhibitors: the journey from research hypothesis to clinical approval.A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.

P2860

Q26753159-7B71F1B9-0415-4DAD-A4B7-4C14D6E2798E Q30413950-7AB3CE10-E10E-489A-A95E-6C064878F9BD Q34493362-69034C38-559C-46E1-9D7B-6B143293D64B Q34558399-C9A3A1B3-957A-46E9-861B-991E0A9F5BE6 Q34769289-95A7910C-4382-4DB4-8E98-A7482BBF4DDB Q35837949-4E1C1E1B-FA65-4365-A7B5-904702103D8C Q36038823-FB0907FA-B013-42DE-BC5D-6381380BF5E8 Q36111892-9CCD2C0B-DCC7-4C4A-9685-619D685AE30D Q36490203-DEA75CB7-F5E0-41B9-AA86-4F173F9D40C0 Q36548227-17A910F4-820D-4A3B-9912-8BDE8248EF59 Q37309834-D7235DD5-3407-4F92-9C70-A51D2D42AD57 Q37669695-DF4046C3-2CFD-4AAB-A66C-B2909A9B00DD Q38015737-FB033176-FB7D-4D09-B167-8AA7F9579B4D Q38047648-7B6E2ABF-D180-4022-9F09-B8DC2D763359 Q38085600-C73BC14D-BE49-4B0B-92E3-FB19BC9156D7 Q38106985-65E93564-2C1D-4261-A774-156B759D1CA2 Q38137526-DB921483-4DE8-41FB-9B3F-83A0B1610B5B Q38258602-0974DB9E-66E9-49C4-B290-B411BFB63485 Q38692827-882AEFB8-12C2-4986-A0D9-E99A9CAB1808 Q38720911-A96F060D-A4ED-4BBD-A2F2-8C1AA2E63C26 Q38722189-1D79F71A-1C70-45BC-84D0-7FFF70C9636C Q38743147-25371D89-8C3C-47EB-944A-270C3D48A37D Q38917645-505FD1A3-0273-4703-8B09-AC8B88BE7252 Q38981181-6D78C88C-061F-4A83-A094-661FB3736E7F Q39078422-AD6B995C-1499-4BAD-9C18-6D760509F6D4 Q39082252-7DC6089D-3B9E-4C07-9322-82C610888E4C Q39159676-B5A2C6C3-3CBE-408E-9E96-456729037499 Q39455545-B3E6F2DB-CB58-423A-AA2C-3C5E116B4234 Q41472052-67A26AC2-BAE9-47B7-A36D-BA9A92DE6199 Q41529398-99011E7F-7C57-4B84-B604-40E3E5BC80CE Q42672281-3CCC57C3-0AF9-415E-923D-BED8295AC106 Q50540192-DD58D37F-C950-4A5E-B7E4-3E5CD3756638 Q52721696-69C0DE28-233C-4415-AFCD-C53DE503122F Q53682668-220677E8-0A32-4429-88BA-8E7BD2807933 Q54487776-39836F47-6031-443D-8603-DB5EB3076078

P2860

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

http://www.wikidata.org/entity/Q34539782

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@ast

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@en

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@nl

type

label

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@ast

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@en

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@nl

prefLabel

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@ast

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@en

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@nl

P1433

Q34539782-23E6E993-A68D-4928-8A26-BFBBB1D07802

P1476

Q34539782-660E34F8-F540-4C92-B426-C0087464C3DA

P2093

Q34539782-EBFDA341-DCED-4E07-B7B9-F3C5D4428C6F

Q34539782-F7B361B3-2EBC-41D7-84CC-EF992BAD37F3

P2860

Q34539782-06DBAAE9-7F8D-4F7A-B39B-E5B190F1B4D0

Q34539782-080C7840-C0A9-49C5-8AA5-F9533089B53F

Q34539782-0CE6B6B4-52E1-4859-9207-7C9DA7D7B865

Q34539782-135D2DBE-012B-4B93-AA7D-C9B111D632BE

Q34539782-183C1B86-5C2A-42E1-884B-4D69DE94C92C

Q34539782-190876A5-FE4B-4097-9536-C8DBE1491200

Q34539782-198E138D-44E5-451B-A83E-17FD9825CB99

Q34539782-1B009DE0-C235-4101-ABE7-4B80229B2021

Q34539782-1B1BC5E9-A9C1-4B0A-957F-3CBDE127C654

Q34539782-22C398CF-89D3-4744-BC8C-62950F197853

P304

Q34539782-C7FA7AE5-E07E-48C2-916C-598AC376A30D

P31

Q34539782-8306A5CD-2FD7-45B2-B765-D1BEDB0024C3

P356

Q34539782-C0BF7299-612C-4452-BCC0-22978F6FB9BA

P433

Q34539782-2A51DA06-79F4-43F6-AFEF-CD0B100747B1

P478

Q34539782-A33C6415-D8AB-423E-A764-A9C604EFE772

P577

Q34539782-C0BBDB4D-8F8D-4E93-BF35-42C65439FE20

P5875

Q34539782-75AF59D4-63AD-440B-8C59-BADD06251B1B

P698

Q34539782-948D8E99-1843-4B06-9D50-2720823E024C

P932

Q34539782-D507596D-D4C6-41A5-B9C2-CBB6B70EDF49

P356

P1433

Journal of molecular cell biology

P1476

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

@en

P2093

Amal Aly

http://www.w3.org/2001/XMLSchema#string

Shridar Ganesan

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a carboxy-terminal BRCA1 interacting protein

BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function

Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins

Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response

RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

CCDC98 targets BRCA1 to DNA damage sites

Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1

Identification of a RING protein that can interact in vivo with the BRCA1 gene product

XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage

P304

66-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JMCB/MJQ055

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49795793

http://www.w3.org/2001/XMLSchema#string

P698

21278454

http://www.w3.org/2001/XMLSchema#string

P932

3030974

http://www.w3.org/2001/XMLSchema#string